Welcome to our dedicated page for Putnam BioRevolution ETF news (Ticker: SYNB), a resource for investors and traders seeking the latest updates and insights on Putnam BioRevolution ETF stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Putnam BioRevolution ETF's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Putnam BioRevolution ETF's position in the market.
Franklin Templeton (NYSE:BEN) has announced the liquidation of its Putnam BioRevolution™ ETF (SYNB). The fund will cease accepting creation unit orders after October 24, 2025, and redemption orders after November 13, 2025.
Trading on NYSE Arca will be suspended before market open on November 14, 2025. The final liquidation is scheduled for November 21, 2025, when remaining shareholders will receive pro rata cash distributions after all fund obligations are met.
FAQ
What is the current stock price of Putnam BioRevolution ETF (SYNB)?
